Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1946 1
1947 1
1948 1
1950 3
1951 1
1952 4
1953 3
1954 4
1955 1
1956 2
1957 1
1958 6
1959 2
1960 5
1961 9
1962 4
1963 5
1964 4
1965 2
1966 2
1967 3
1968 4
1969 2
1970 3
1971 3
1972 3
1973 4
1974 4
1975 4
1977 5
1978 6
1979 5
1980 8
1981 7
1982 6
1983 4
1984 4
1985 4
1986 12
1987 4
1988 9
1989 14
1990 8
1991 9
1992 8
1993 13
1994 23
1995 20
1996 31
1997 26
1998 14
1999 24
2000 19
2001 27
2002 20
2003 25
2004 34
2005 37
2006 41
2007 43
2008 43
2009 42
2010 32
2011 39
2012 46
2013 48
2014 59
2015 71
2016 74
2017 75
2018 80
2019 71
2020 85
2021 110
2022 101
2023 94
2024 96
2025 93
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,682 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: spencer a. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC. Avet-Loiseau H, et al. Among authors: spencer a. J Clin Oncol. 2025 Aug 20;43(24):2739-2751. doi: 10.1200/JCO-24-01893. Epub 2025 Jun 9. J Clin Oncol. 2025. PMID: 40489728
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. San-Miguel J, et al. Among authors: spencer a. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272512 Clinical Trial.
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.
Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R, Schjesvold F, Gay F, Manier S, Weisel KC, Kaiser M, van de Donk NWCJ, Zamagni E, Rodriguez-Otero P, Perrot A, Driessen C, Bila J, Laane E, Dytfeld D, Touzeau C, Beksac M, Raab MS, Cavo M, Mohty M, Spencer A, Ludwig H, Einsele H, San-Miguel J, Sonneveld P. Dimopoulos MA, et al. Among authors: spencer a. Nat Rev Clin Oncol. 2025 Sep;22(9):680-700. doi: 10.1038/s41571-025-01041-x. Epub 2025 Jul 7. Nat Rev Clin Oncol. 2025. PMID: 40624367 Review.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Sonneveld P, et al. Among authors: spencer a. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. doi: 10.1200/JCO.21.02734. Epub 2022 Nov 22. J Clin Oncol. 2023. PMID: 36413710 Free PMC article. Clinical Trial.
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.
Musto P, Engelhardt M, van de Donk NWCJ, Gay F, Terpos E, Einsele H, Fernández de Larrea C, Sgherza N, Bolli N, Katodritou E, Gentile M, Royer B, Derudas D, Jelinek T, Zamagni E, Rosiñol L, Paiva B, Caers J, Kaiser M, Beksac M, Hájek R, Spencer A, Ludwig H, Cavo M, Bladé J, Moreau P, Mateos MV, San-Miguel JF, Dimopoulos MA, Boccadoro M, Sonneveld P. Musto P, et al. Among authors: spencer a. Ann Oncol. 2025 Apr;36(4):361-374. doi: 10.1016/j.annonc.2025.01.022. Epub 2025 Feb 7. Ann Oncol. 2025. PMID: 39924085 Free article. Review.
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.
Minnie SA, Waltner OG, Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, Schmidt CR, Legg SRW, Comstock M, Boiko JR, Nelson E, Bhise SS, Wilkens AB, Koyama M, Dhodapkar MV, Chesi M, Riddell SR, Green DJ, Spencer A, Furlan SN, Hill GR. Minnie SA, et al. Among authors: spencer a. Sci Immunol. 2024 Apr 19;9(94):eadg1094. doi: 10.1126/sciimmunol.adg1094. Epub 2024 Apr 19. Sci Immunol. 2024. PMID: 38640253 Free PMC article.
Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
Gulbins A, Horstmann M, Daser A, Flögel U, Oeverhaus M, Bechrakis NE, Banga JP, Keitsch S, Wilker B, Krause G, Hammer GD, Spencer AG, Zeidan R, Eckstein A, Philipp S, Görtz GE. Gulbins A, et al. Among authors: spencer ag. Front Endocrinol (Lausanne). 2023 Jun 26;14:1211473. doi: 10.3389/fendo.2023.1211473. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37435490 Free PMC article.
1,682 results